A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (13th August 2019) - Kulke, M H; Ruszniewski, P; Van Cutsem, E; Lombard-Bohas, C; Valle, J W; De Herder, W W; Pavel, M; Degtyarev, E; Brase, J C; Bubuteishvili-Pacaud, L; Voi, M; Salazar, R; et al.